Puma Biotechnology, Inc. (PBYI)

$2.78

-0.07 (-2.46%)
Rating:
Recommendation:
Neutral
Symbol PBYI
Price $2.78
Beta 1.059
Volume Avg. 0.48M
Market Cap 125.025M
Shares () -
52 Week Range 1.6-8.9
1y Target Est -
DCF Unlevered PBYI DCF ->
DCF Levered PBYI LDCF ->
ROE -844.14% Strong Sell
ROA -24.44% Sell
Operating Margin -
Debt / Equity 2708.75% Strong Buy
P/E -
P/B 16.42 Strong Buy
Annual
Quarter

Earnings

Consensus EPS

Upgrades & Downgrades

Latest PBYI news


Mr. Alan Auerbach
Healthcare
Biotechnology
NASDAQ Global Select

Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. The company's drug candidates include PB272 neratinib (oral) for the patients with early stage HER2-overexpressed/amplified breast cancer; PB272 (neratinib, oral) for the use of neratinib in combination with capecitabine for the treatment of adult patients with advanced or metastatic HER2-positive breast cancer; PB272 (neratinib, oral) for HER2 mutation-positive solid tumors. It has a license agreement with Pfizer, Inc.; and sub-license agreement with Specialised Therapeutics Asia Pte Ltd., CANbridge BIOMED Limited, Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. The company was founded in 2010 and is headquartered in Los Angeles, California.